New therapy shrinks tumors to treat lung cancer
Researchers at Stony Brook Cancer Center have developed a new therapy, Gem-miR-129, that combines a tumor-suppressor molecule with chemotherapy to treat non-small cell lung cancer. In laboratory models, the treatment successfully shrank tumors by over 95% and extended survival times.
Why it matters
This breakthrough offers a potential new strategy to overcome drug resistance in lung cancer, which remains a leading cause of cancer-related mortality.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Graphical abstract. Credit: Molecular Therapy Nucleic Acids (2026). DOI: 10.1016/j.omtn.2026.102997 The need for more effective lung cancer treatments is paramount, as the disease remains a leading cause of cancer deaths in the United States. New findings by a research team from the Stony Brook Cancer Center highlight a novel therapeutic shown to be highly effective in reducing non-small cell lung cancer (NSCLC) tumors and appearing to halt drug resistance in a laboratory model.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in